Parameter | Unit cost, USD | Price, USD | Table Column Head | ||||||
Neoadjuvant chemotherapy | Stable | Progression and hormonal chemotherapy | Progression and chemotherapy | ||||||
Utility |
|
|
| 0.89 | 0.85 | 0.74 | |||
|
|
|
|
|
|
| |||
Epirubicin (100 mg/m2), 10 mg/V | 39.2 | 588.2 | ● | - | - | - | |||
5-Fu (500 mg/m2), 250 mg/V | 3.1 | 9.2 | ● | - | - | - | |||
Cyclophosphamide (500 mg/m2), 500 mg/V | 11.4 | 22.7 | ● | - | - | - | |||
Granisetron hydrochloride (3 mg/body) | 32.1 | 32.1 | ● | - | - | - | |||
Zoledronic acid (4 mg/body), 4 mg/V | 254.3 | 254.3 | ● or -* | - | - | - | |||
Paclitaxel (80 mg/m2), 30 mg/V | 66.2 | 264.9 | ● | - | - | - | |||
Tamoxifen (20 mg/day), 20 mg/1T | 4.1 | 4.1 | - | ● | ● | - | |||
Leuprorelin acetate (11.25 mg/body), 11.25 mg/1KT | 605.9 | 605.9 | - | - | ● | - | |||
Vinorelbine bitartrate (25 mg/m2), 40 mg/V | 160.0 | 160.0 | - | - | - | ● | |||
Extended-release oxycodone (40 mg/day), 20 mg/1T | 4.2 | 8.5 | - | - | - | ● | |||
Quick-release oxycodone, 5 mg | 1.0 | 3.1 | - | - | - | ● | |||
Surgery (inpatient/day) | 249.8 | 2248.4 | ● | - | - | - | |||
Radiation (50 Gy) | 17.2 |
| - | ● | - | - | |||
|
|
|
|
|
| ||||
Hepatitis screening |
| 35.7 | ● | - | - | - | |||
Cardiac function test |
| 91.5 | ● | - | - | - | |||
CT scan with contrast medium |
| 146.7 | ● | ● | ● | ● | |||
Contrast medium |
| 61.2 | ● | ● | ● | ● | |||
CT scan diagnostic fee |
| 50.9 | ● | ● | ● | ● | |||
Administration fee for chemotherapy |
| 62.9 | ● | - | - | ● | |||
Biochemical test diagnostic fee |
| 51.1 | ● | ● | ● | ● | |||
Immunology test diagnostic fee |
| 16.8 | ● | ● | ● | ● | |||
Blood test diagnostic fee |
| 21.7 | ● | ● | ● | ● | |||
Outpatient service fee |
| 42.8 | - | ● | ● | ● | |||
Prescription fee |
| 6.3 | - | ● | ● | ● | |||
Ultrasound test |
| 31.7 | ● | ● | ● | ● | |||
Bone metastasis test |
| 481.2 | - | ● | ● | ● | |||
Total cost per annum, USD |
|
| CTZ: 5905.3 CT: 3870.9 |
|
|
| |||
Total cost per patient cycle (month), USD |
|
| - | 438.9 | 1123.6 | 1473.1 | |||